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Background and Objective: Platelet-derived growth factor-BB is a potent mediator
of tooth-supporting periodontal tissue repair and regeneration. A limitation of the
effects of topical platelet-derived growth factor-BB application is its short half-life
in vivo.Gene therapyhas shown strongpromise for the long-termdelivery of platelet-
derived growth factor in both skin ulcer healing and periodontal tissue engineering.
However, little is known regarding the extended effects of platelet-derived growth
factor-B on cell signaling via gene delivery, especially at the level of phosphorylation
of intracellular kinases. This study sought to evaluate the effect of gene transfer by
Ad-PDGF-B on human gingival fibroblasts (HGFs) and the subsequent regulation
of genes and cell-surface proteins associated with cellular signaling.
Material and Methods: HGFs from human subjects were treated by adenoviral
PDGF-B, PDGF-1308 (a dominant negative mutant of PDGF) and recombinant
human platelet-derived growth factor-BB, and then incubated in serum-free
conditions for various time points and harvested at 1, 6, 12, 24, 48, 72 and 96 h.
Exogenous PDGF-B was measured by RT-PCR and Western blot. Cell
proliferation was evaluated by [methyl-3H]thymidine incorporation assay. We
used proteomic arrays to explore phosphorylation patterns of 23 different
intracellular kinases after PDGF-B gene transfer. The expression of a and b
PDGFR and Akt were measured by Western blot analysis.
Results: Sustained in vitro expression of PDGF-B in HGFs by Ad-PDGF-B
transduction was seen at both the mRNA and protein levels. Compared to
rhPDGF-BB and Ad-PDGF-1308, Ad-PDGF-B maintained cell growth in serum-
free conditions, with robust increases in DNA synthesis. Gene delivery of PDGF-B
also prolonged downregulation of the growth arrest specific gene (gas) PDGFaR.
Of the 23 intracellular kinases that we tested in proteomic arrays, Akt revealed the
most notable long-term cell signaling effect as a result of the over-expression of
Ad-PDGF-B, compared with pulse recombinant human platelet-derived growth
factor BB. Prolonged Akt phosphorylation was induced by treatment with
Ad-PDGF-B, for at least up to 96 h.
Conclusion: These findings further demonstrate that gene delivery of PDGF-B
displays sustained signal transduction effects in human gingival fibroblasts that are
higher than those conveyed by treatment with recombinant human platelet-derived
growth factor-BB protein. These data on platelet-derived growth factor gene
delivery contribute to an improved understanding of these pathways that are likely
to play a role in the control of clinical outcomes of periodontal regenerative
therapy.
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Platelet-derived growth factor, a
member of a multifunctional polypep-
tide family, is composed of A, B, C
and D polypeptide chains that form
homodimeric or heterodimeric mole-
cules (1). Two receptor isoforms with
tyrosine kinase activity have been
identified: platelet-derived growth fac-
tor-a receptor and platelet-derived
growth factor-b receptor (1). Platelet-
derived growth factor binding to
receptors activates a variety of intra-
cellular signal molecules, such as
phosphatidylinositol-3-kinase and Akt/
PKB, and subsequently exerts its
biological effects on cell migration,
proliferation, extracellular matrix syn-
thesis and anti-apoptosis (2–7).
Platelet-derived growth factor-BB,
which binds both a and b platelet-
derived growth factor receptors, pro-
motes wound healing in both hard and
soft tissues, such as skin and perio-
dontium. Platelet-derived growth fac-
tor-a and -b receptors are induced in
human gingival fibroblasts and tooth-
supporting periodontal ligament cells
during periodontal tissue repair (8,9).
In addition, platelet-derived growth
factor initiates tooth-supporting perio-
dontal ligament cell chemotaxis (10),
mitogenesis (11), matrix synthesis
(12,13) and attachment to tooth den-
tinal surfaces (14). In an experimental
model of periodontitis in macaques,
platelet-derived growth factor-BB was
shown to promote new attachment and
new bone formation in vivo (15). Fur-
thermore, it has been recently shown
that the application of platelet-derived
growth factor-BB in an osteoconduc-
tive scaffold promotes periodontal
regeneration in humans (16).
A limitation of the effects of topical
platelet-derived growth factor applica-
tion is its short half-life in vivo (17–19).
Genedelivery is a candidate approach to
overcome this problem. Delivery of
platelet-derived growth factor by gene
transfer has been shown to stimulate the
mitogenesis and proliferation of gingi-
val fibroblasts, periodontal ligament
and tooth-lining cells (cementoblasts)
more strongly than the continuous
administration of platelet-derived
growth factor protein in vitro (20,21).
In terms of gene expression duration,
in vitro studies have shown that adeno-
virus-encoded platelet-derived growth
factor-A delivered to cells derived from
periodontal tissues (gingival and perio-
dontal ligament fibroblasts, cemento-
blasts and osteoblasts) elicits elevated
and prolonged expression of the
PDGF-A gene for at least 1 wk (20,22).
Furthermore, transfer of the PDGF-A
gene using adenovirus resulted in sus-
tained tyrosine kinase phosphorylation
and downregulation of the platelet-
derived growth factor-a receptor for
at least 96 h in dermal fibroblasts (22).
Our previous work has also shown that
in vivo,PDGF-B gene transfer promotes
the regeneration of tooth- supporting
structures when adenovirus-encoded
PDGF-B is applied to periodontal
osseous defects (23). Another study
examined the effect of gene transfer by
adenovirus encoding PDGF-A and
PDGF-B on a human gingival fibroblast
repopulation in an ex vivo wound-heal-
ing model and found that gene expres-
sionwasmaintained for at least 10 dand
that PDGF-B gene transfer stimulated
an increase ofmore than four-fold in cell
repopulation above that of PDGF-A
and controls (24). Although adenoviral
delivery of PDGF-B demonstrates a
promising future in periodontal regen-
eration, little is known about its long-
term effect on signal transduction in
cells isolated from the periodontium.
Human gingival fibroblasts are a possi-
ble cell target for periodontal tissue
regeneration because of several advan-
tages, such as easy accessibility, richness
in cell resource and higher proliferation
potential. In our previouswork,wehave
already shown that human gingival
fibroblasts can respond to adenoviral-
encoded platelet-derived growth factor-
A (21) and can be used to stimulate
periodontal soft tissue repair ex vivo
(24). The present study sought to eval-
uate the effect of gene transfer ofPDGF-
B by adenovirus on human gingival
fibroblasts and the subsequent regula-
tion of genes and cell-surface proteins
associated with cellular signaling.
Material and methods
Adenovirus construction
The construction of the adenovirus
encoding PDGF-1308 (the dominant
negative mutant of platelet-derived
growth factor-A) has been previously
described (25). The recombinant ade-
noviruses encoding human PDGF-B
(Ad-PDGF-B) and luciferase (Ad-Luc)
are driven by a cytomegalovirus pro-
moter and were gifts from Tissue
Repair Company (26), San Diego, CA,
USA.
Cell culture and gene transduction
Primary human gingival fibroblasts
used for this study were kindly gifted
to us by Dr Martha Somerman (Uni-
versity of Washington, Seattle, WA,
USA). Human gingival fibroblasts
were isolated separately from gingival
tissue biopsy samples from three heal-
thy human patients. Low passage cells
(passages 4–7) were cultured and
maintained in Dulbeccos modified
Eagles minimal essential medium
supplemented with 10% fetal bovine
serum, 100 U/mL of penicillin/strep-
tomycin and 2 mM glutamine, then
plated in 60 · 15-mm dishes. Conflu-
ent cultures were brought to a stage of
quiescence by rinsing the monolayers
with phosphate-buffered saline and
reducing the serum concentration to
0.1% for 24 h prior to adenovirus
transduction or treatment with
recombinant human platelet-derived
growth factor-BB (a kind gift of
BioMimetic Therapeutics Inc., Frank-
lin, TN, USA). For all experiments the
cells were treated either with recombi-
nant adenoviruses (Ad-PDGF-B,
Ad-PDGF-1308, Ad-Luc) for 2 h at a
multiplicity of infection of 200 or with
20 ng/mL of recombinant human
platelet-derived growth factor-BB.
Cells were incubated for various
periods of time and harvested at 1, 6,
12, 24, 48, 72 and 96 h.
[Methyl-3H]thymidine incorporation
assay
Human gingival fibroblast cells were
seeded in 12-well plates at a concen-
tration of 2 · 104 cells per well. After
different treatments (recombinant
human platelet-derived growth factor-
BB, Ad-PDGF-B, Ad-PDGF-1308 or
no treatment), cells were cultured with
serum-free Dulbeccos modified Eagles
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minimal essential medium. Two days
later, 2 · 105 counts per minute of
[methyl-3H]thymidine was added to
each well. On day 7, the medium was
removed and each well was washed
twice with cold phosphate-buffered
saline. The DNA in each well was
precipitated with 5% cold trichloro-
acetic acid at 4C for 2 h, solubi-
lized with 1% sodium dodecyl sulfate
solution at 55C for 2 h and then the
radioactivity of [methyl-3H]thymidine
in the solution was counted using a
scintillation counter (Wallac 1410;
Perkin-Elmer, Waltham, MA, USA).
Western blot analysis
Whole-cell lysates were obtained from
transduced human gingival fibroblast
cells by washing cell monolayers twice
with ice-cold phosphate-buffered sal-
ine, adding 250 lL of ice-cold cell lysis
buffer (Bio-Rad, Alameda, CA, USA)
directly to each dish and harvesting
using cell scrapers. The total protein
concentration was determined using
the Bio-Rad Protein Assay with mea-
surement of the absorbance at 595 nm.
After heat denaturation (95C, 5 min),
10 lg of total protein from each sam-
ple was added to 5· sample buffer
(0.06 M Tris, pH 6.8, 2% sodium
dodecyl sulfate, 0.3 M b-mercaptoeth-
anol, 0.1% bromophenol blue, 10%
glycerol) and the samples were elec-
trophoresed (80 V, 2 h) through 10%
acrylamide gels in Tris-glycine-sodium
dodecyl sulfate running buffer. Protein
samples were then transferred to
immunoblot poly(vinylidene difluo-
ride) membranes (Bio-Rad) in transfer
buffer, pH 8.3 (25 mM Tris, 192 mM
glycine, 20% methanol) for 90 min at
400 mA in a 4C cold room. The
membrane was then incubated in
TTBS (100 mM Tris, 0.9% NaCl, 0.5%
Tween 20) containing 5% nonfat dry
milk for 1 h to block nonspecific
binding. The blocking solution was
discarded and the membrane was
incubated overnight in fresh blocking
solution containing diluted primary
antibodies. The membranes were then
washed with TTBS for 15 min, three
times, then incubated in fresh blocking
solution containing a 1:3000 dilution of
anti-rabbit horseradish peroxidase
(Amersham Corp. Piscataway, NJ,
USA) for 1 h. The membranes were
washed as described above and pre-
pared for chemiluminescent detection
by immersing the blot in a 1:1 mixture
of reagents from an ECL Detection Kit
(Amersham Corp.), then exposed to
Biomax MS film (Kodak, Rochester,
NY, USA) for 30–120 s before devel-
opment. Densitometric scanning (Bio-
Rad Molecular Imager ChemiDoc
XRS System; Bio-Rad) was performed
by normalizing platelet-derived growth
factor receptor expression to glyceral-
dehyde-3-phosphate dehydrogenase
for each of the treated primary cell
cultures from three different human
biopsies to ascertain receptor expres-
sion patterns following gene or protein
delivery. Antibodies used in the present
study were: rabbit anti-human platelet-
derived growth factor-a receptor poly-
clonal antibody and rabbit anti-human
platelet-derived growth factor-b recep-
tor polyclonal antibody (Upstate Cell
Signaling, Charlottesville, VA, USA),
rabbit polyclonal anti-phospho-Akt
(Ser473) , rabbit polyclonal anti-Akt,
rabbit polyclonal anti-GAPDH (all
from Cell Signaling Technology, Dan-
vers, MA, USA). In order to detect the
secreted platelet-derived growth factor-
BB, cell culture medium was collected
on day 4, followed by dialysis in Am-
icon Ultra spin columns (Millipore,
Billerica, MA, USA) and lyophiliza-
tion. Then, the samples were reconsti-
tuted in H2O and loaded for western
blot analysis. Rabbit polyclonal anti-
platelet-derived growth factor-B (Santa
Cruz Biotechnology, Santa Cruz, CA,
USA) was used to detect platelet-de-
rived growth factor-B expression.
Reverse transcription-polymerase
chain reaction
Total RNA was extracted from human
gingival fibroblast cells using the
Qiagen RNeasy Mini kit (Qiagen,
Valencia, CA, USA). Approximately
1 lg of RNA was reverse transcribed
in a 20-lL reverse transcription reac-
tion using a Retroscript kit (Ambion,
Austin, TX, USA). cDNA was gener-
ated using random primers. Ten micro-
liters of the cDNA was used as a
template for polymerase chain reaction
amplification to detect PDGF-B as well
as the housekeeping gene, GAPDH.
Proteomic array for phosphoproteins
In order to assess the relative level
of phosphorylation in a given sample,
a human Phospho-MAPK array kit
(R&D Systems, Minneaplolis, MN,
USA) was utilized to measure simul-
taneously the phosphorylation levels of
23 different mitogen-activated protein
kinases (MAPKs) and other serine/
threonine kinases. Each array contains
duplicate validated control and capture
antibodies for specific kinases. The
MAPK array was performed according
to the manufacturers protocol. Briefly,
human gingival fibroblast cells that
had undergone the different experi-
mental treatments were lysed using the
lysis buffer in the kit. Array mem-
branes were blocked at room temper-
ature for 1 h and were then incubated
with 800 lg of total cell lysate over-
night at 4C. The next day, after
washing three times, array membranes
were incubated with a phospho-site
specific biotinylated antibody cocktail
for 2 h at room temperature. The
membranes were washed a further
three times, developed using the ECL
Detection Kit (Amersham), then
exposed to Biomax MS film (Kodak).
Results
Adenoviral gene delivery of PDGF-B
results in sustained expression of
platelet-derived growth factor-BB in
human gingival fibroblast cells
We first assessed the expression of
exogenous PDGF-B in primary human
gingival fibroblasts by adenoviral gene
delivery. In our previous study, using
green fluorescent protein reporter pro-
tein, we showed that adenoviral gene
delivery has a high transduction effi-
ciency in fibroblasts (> 95% of dermal
fibroblasts were transduced) (22).
Similarly, in the present study we
detected the transcription of exogenous
PDGF-B 6 h after exposure to
Ad-PDGF-B, and transcription was
sustained for at least 96 h (Fig. 1A).
This effect was not observed after
transfection of either the Ad-Luc con-
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trol (Fig. 1A) or Ad-PDGF-1308 (data
not shown). Furthermore, exogenously
expressed PDGF-B was translated and
secreted into cell culture medium as a
dimer, which was detected by western
blot analysis 4 d after treatment with
Ad-PDGF-B but not after treatment
with Ad-PDGF-1308 (Fig. 1B). Our
Ad-PDGF-B vector encodes a 160
amino acid platelet-derived growth
factor-B isoform with a molecular
weight of 18.1 kDa; therefore, in non-
reducing conditions, this results in a
dimer of about 36.2 kDa. For the
recombinant human platelet-derived
growth factor-BB control, the dimer of
the 109 amino acid isoform displayed a
molecular weight of 25 kDa.
Adenoviral gene delivery of PDGF-B
maintains human gingival fibroblast
proliferation
Next, we sought to determine whether
the exogenous expression of PDGF-B
was biologically active. After treatment
with Ad-PDGF-B, human gingival
fibroblasts tended to form greater cell
polarization distinct from that observed
following treatment with recombinant
human platelet-derived growth factor-
BB or with the Ad-PDGF-1308 control
(Fig. 2A). Compared to treatment
with Ad-PDGF-1308 or transient
recombinant human platelet-derived
growth factor-BB, Ad-PDGF-B
administration maintained the prolifer-
ation of human gingival fibroblasts in
serum-free conditions and stimulated
robust DNA synthesis, as shown by the
[methyl-3H]thymidine-incorporation
assay (Fig 2B).
Gene delivery of Ad-PDGF-B
prolonged downregulation of the
growth arrest-related gene PDGFaR
and of PDGFbR
In the condition of serum deprivation,
fibroblasts remain in the state of growth
arrest (G0), which is associated with in-
creased expression of the gas gene
PDGFaR as well as of PDGFbR. We
examined the impact of Ad-PDGF-B
transduction on the levels of platelet-
derived growth factor-a receptor and
platelet-derived growth factor-b recep-
tor. The steady-state levels of platelet-
derived growth factor-a receptor and
platelet-derived growth factor-b recep-
tor for the Ad-PDGF-1308-treated hu-
man gingival fibroblasts remained at
similar levels over the 96-h observation
period. Treatment of human gingival
fibroblasts with recombinant human
platelet-derived growth factor-BB pro-
tein elicited a reduction in the levels of
platelet-derived growth factor-a recep-
tor and platelet-derived growth factor-b
receptor within 1 h and these levels
remained low for 12 h before returning
to normal baseline levels by 24 h
(Fig 3). By contrast, human gingival
fibroblast cells treated with Ad-PDGF-
B (multiplicity of infection = 200)
showed a delayed, but prolonged and
greater, reduction in both platelet-
derived growth factor-a and -b receptor
protein levels starting at about 24 h,
with the levels remaining reduced for at
least 96 h (Fig. 3).
Proteomic array to determine
phosphorylation of intracellular
proteins
In these experiments our goal was to
identify the effects on signal transduc-
A
B
Fig. 1. Adenoviral gene delivery of PDGF-B results in the sustained expression of platelet-
derived growth factor-B in human gingival fibroblast cells. (A) Human gingival fibroblast
cells were cultured to confluence and were then transferred to serum-free medium containing
Ad-PDGF-B (multiplicity of infection = 200), Ad-Luc, Ad-PDGF-1308, or platelet-derived
growth factor-BB protein (20 ng/mL). The cells were then allowed to incubate for 2–3 h
before removal and replacement with serum-free medium. The cells were then harvested for
RNA extraction at 6, 12, 24, 48, 72 and 96 h post-infection. Approximately 1.0 lg of total
RNA was then used to generate cDNA with oligo dT primers. The resulting cDNA was used
as a template for polymerase chain reaction amplification using human gene-specific primers
for PDGF-B or GAPDH. The results show that only the treatment with Ad-PDGF-B caused
a measurable increase in PDGF-B gene expression. The results obtained following treatment
with Ad-Luc, Ad-PDGF-1308 or platelet-derived growth factor-BB protein showed no
detectable expression of the PDGF-B gene (data not shown). (B) Approximately 2 · 105 cells
were seeded in 100-cm dishes. After transient infection with Ad-PDGF-1308 or Ad-PDGF-B,
the cells were cultured in serum-free medium. Conditioned media were collected at 96 h.
After dialysis and lyophilization, samples were reconstituted in H2O, loaded for non-reduced
sodium dodecyl sulfate-polyacrylamide gel electrophoresis, and detected using anti-PDGF-
BB. Our Ad-PDGF-B vector encodes a 160 amino acid platelet-derived growth factor-B
isoform with a molecular weight of 18.1 kDa; therefore, a dimer in the non-reduced SDS gel
was about 36.2 kDa. For the recombinant human platelet-derived growth factor-BB control,
the dimer of the 109 amino acid isoform displayed a molecular weight of 25 kDa. hGAPDH,
human glyceraldehyde-3-phosphate dehydrogenase; PDGF-B, platelet-derived growth
factor-B; rhPDGF-BB, recombinant human platelet-derived growth factor-BB.
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tion elicited by Ad-PDGF-B gene
delivery. After recombinant human
platelet-derived growth factor-BBbinds
to tyrosine receptor kinases, it triggers a
cascade of downstream signal trans-
duction pathways, in which kinase
activation plays a central role. Because
we observed (by western blotting)
prolonged downregulation of platelet-
derived growth factor-a and -b receptor
protein levels following treatment with
Ad-PDGF-B, we wanted to determine
whether adenoviral delivery would also
extend intracellular signaling events.
Therefore, we examined the phosphor-
ylation state of numerous kinases by
using a human phospho-MAPK array
that contains 21 different specific intra-
cellular kinase antibodies (Table 1).
This array allowed the simultaneous
relative quantification of the phos-
phorylation state of MAPKs in three
major families (ERK1/2, JNK1–3 and
p38), and also detected another nine
important intracellular tyrosine/serine
kinases, including Akt, GSK-3 and p70






Fig. 2. (A) Cells were treated as described in the legend to Fig. 1 and photographed at 72 h. Compared to treatment with control (serum-
free), Ad-PDGF-1308, or recombinant human platelet-derived growth factor-BB, human gingival fibroblasts transduced with Ad-PDGF-B
resulted in colony-like growth, as indicated by the arrows (20· magnification). (B) Human gingival fibroblast cells were seeded in 12-well
plates at a concentration of 2 · 104 cells per well. After different treatments (recombinant human platelet-derived growth factor-BB,
Ad-PDGF-B, or Ad-PDGF-1308), the cells were cultured with serum-free Dulbeccos modified Eagles minimal essential medium without
medium change during the experiment. Two days later, 2 · 105 counts per minute of [methyl-3H]thymidine was added to each well. On day 7,
the medium was removed and each well was washed twice with cold phosphate-buffered saline. The DNA in each well was precipitated with
5% cold trichloroacetic acid at 4C for 2 h, solubilized with 1% sodium dodecyl sulfate solution at 55C for 2 h, then the radioactivity of
[methyl-3H]thymidine in the solution was counted using a scintillation counter. Ad-PDGF-B stimulated robust DNA synthesis when com-
pared with the other treatments. NS, no significant difference; (n = 6 samples).
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(Table 1).With this arraywe focused on
phophorylation patterns at early stage
(1 h) and late-stage (72 h and 96 h)
time-points. Akt1, Akt2 and Akt3 were
the most sensitive intracellular signal
markers to platelet-derived growth fac-
tor treatment of all the 21 kinases that
were tested.Our results showed thatAd-
PDGF-B treatment revealed a similar,
but delayed, phosphorylation pattern as
that of recombinant human platelet-
derived growth factor-BB: significant
Akt phosphorylation was seen by 1 h
after stimulation of human gingival
fibroblasts by recombinant human
platelet-derived growth factor-BB, but
the effect disappeared by 72 h; exposure
to Ad-PDGF-B resulted in Akt phos-
phorylation at the late stage, which can
be seen from arrays at both 72 and 96 h
(Fig. 4). Unstimulated human gingival
fibroblast lysates demonstrated very
low basal levels of phosphorylation in
all the tested kinases under serum-
deprivation conditions, and this was
also found for the Ad-PDGF-1308
control.
Sustained phosphorylation of Akt in
adenoviral gene delivery
Based on our findings from the proteo-
mics array,Aktwas further evaluated as
a key intracellular molecule that medi-
ates the biological function of adeno-
viral PDGF gene delivery. These
experiments were designed to explore in
further detail the time curve of Akt
activation during Ad-PDGF-B trans-
duction, compared with exposure to
recombinant human platelet-derived
growth factor-BB. Our results showed
that in cells exposed to recombinant
human platelet-derived growth factor-
BB, phosphorylation of Akt, which
peaked at 1–6 h, was sustained only for
12–24 h. In human gingival fibroblasts
treated with Ad-PDGF-B, the phos-
phorylation of Akt was initially seen as
early as 6 h post-transduction and
remained elevated for at least 96 h, to a
greater relative extent than platelet-
derived growth factor-BB (Fig. 5).
Following Ad-PDGF-1308 delivery,
human gingival fibroblasts did not show
any Akt phosphorylation. We also
examined the phosphorylation of Erk1/
2 in different treatments. Ad-PDGF-B
transduction elicited modest increases
of Erk1/2 phosphorylation at the later
time-points of 48–96 h, a result that was
Fig. 3. GenedeliveryofAd-PDGF-Bprolongs thedownregulationof the growtharrest-related gene (gas)PDGFaRaswell asPDGFbR.Western
blot was used to analyze platelet-derived growth factor-a receptor and platelet-derived growth factor-b expression levels in human gingival
fibroblasts in response to treatment with either recombinant human platelet-derived growth factor-BB (20 ng/mL), or Ad-PDGF-B. Human
gingival fibroblasts from three individuals were tested, with representative data shown here. Human gingival fibroblasts were exposed to
Ad-PDGF-1308 (multiplicity of infection = 200), Ad-PDGF-B (multiplicity of infection = 200) or 20 ng/mL of recombinant human platelet-
derived growth factor-BB in serum-free medium for 2 h. Then, the medium was removed and human gingival fibroblasts were maintained in
serum-free medium for 1, 6, 12, 24, 48, 72 and 96 h. Cells were lysed and 30 lg of total protein from cell lysates was subjected to western blotting
using antibodies to platelet-derived growth factor-a receptor and platelet-derived growth factor-b receptor. The blots were then stripped and
reprobed with anti-GAPDH to determine the relative loading of protein in each lane. Densitometric scanning was performed by normalizing
platelet-derived growth factor receptor expression to glyceraldehyde-3-phosphate dehydrogenase for the treated primary cell cultures from three
different human biopsies. The graphs demonstrate the cumulative results from three individuals with the blots showing the typical result. The
graphs show that treatment with Ad-PDGF-B resulted in sustained downregulation of platelet-derived growth factor-a receptor and platelet-
derived growth factor-b receptor for up to 96 h. GAPDH, glyceraldehyde-3-phosphate dehydrogenase; PDGFaR, platelet-derived growth
factor-a receptor; PDGFbR, platelet-derived growth factor-b receptor; rhPDGF-BB, recombinant human platelet-derived growth factor-BB.
Table 1. Human phosphoproteins simultaneously measured the phosphorylation levels of 21
different mitogen-activated protein kinases (MAPKs) and other serine/threonine kinases
following PDGF-B gene therapy
MAPK family ERK1, ERK2
JNK1, JNK2, JNK3, JNK pan
p38a, p38b, p38c, p38d
Others Akt1, Akt2, Akt3, Akt pan, RSK1, RSK2, MSK2,
GSK-3a/b, GSK-3b, HSP27, p70 S6 kinase
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consistent with our proteomic array
data (data not shown).
Discussion
A major goal of this study was to gain
knowledge of the molecular mecha-
nisms by which adenoviral gene deliv-
ery of PDGF-B mediates periodontal
tissue regeneration. Our previous work
showed that tooth-supporting struc-
tures could be re-engineered by
Ad-PDGF-B. By using human gingival
fibroblast cells, we also demonstrated
that platelet-derived growth factor
gene transfer has a potential use in
periodontal soft tissue-engineering
applications (24). Although the use of
Ad-PDGF-B has enabled several
advancements to be made in the pro-
motion of periodontal regeneration,
little is known about its effects in signal
transduction from cells isolated from
the periodontium. This study examined
some of the cellular signaling events
within human gingival fibroblasts
resulting from adenoviral gene delivery
of PDGF-B compared with direct pro-
tein delivery. This information aids in
an improved understanding of these
pathways that are likely to be critical in
controlling the clinical outcomes of
periodontal regenerative therapies.
Adenoviral vectors are known to be
an effective tool for delivering genes to
a broad range of cell types and tissues
(27). Also, adenovirus has a high
transduction efficiency and does not
integrate into the host genome of the
transduced cells (28). Compared with
the short half-life of recombinant
platelet-derived growth factor protein,
our previous work showed that aden-
oviral gene delivery to rat periodontal
sites induced marker gene expression,
which was maintained at a high level at
least until day 4 and rapidly decreased
to 20% by day 14 (23). Therefore, we
believe that by establishing the changes
in signaling molecules in the first 96 h
after treatment with Ad-PDGF-B we
can understand its extended effects in
more detail. We first examined the
transduction efficiency of PDGF by
Ad-PDGF-B gene transfer to human
gingival fibroblasts using reverse tran-
scription-polymerase chain reaction
and observed a high level of PDGF
gene expression for at least 96 h, and
evident as early as 6 h post-infection
(Fig 1). This correlates well with pre-
vious work by our group and by oth-
ers, which consistently showed a
sustained production of platelet-
derived growth factors delivered by
adenovirus (21,24,29) within other cells
from periodontia. In view of the fact
that some of the platelet-derived
growth factor-BB protein may adhere
to the polymer surface because of
strong negative charges, we would
expect the yield of platelet-derived
Ctrl 
1 h 72 h 96 h
1: Akt-1 
2: Akt-2 1 2
3 4 1 2







Fig. 4. Proteomic array to identify intracellular phosphorylation proteins that mediate either
immediate or long-term effects of protein or gene delivery. The human phospho-MAPK array
kit was utilized tomeasure simultaneously the phosphorylation levels of target kinases.Human
gingival fibroblast cells treated with 20 ng/mL of recombinant human platelet- derived growth
factor-BB, Ad-PDGF-B (multiplicity of infection = 200), Ad-PDGF-1308 (multiplicity of
infection = 200) or serum-free mediumwere harvested at 1, 72 and 96 h post-treatment. After
blocking, 800 lg of human gingival fibroblast cell lysates were incubated with membranes at
4Covernight.Eachmembrane containedduplicates, validated controls and captureantibodies
for specific kinases. After washing, a phospho-site-specific biotinylated antibody cocktail was
added the following day. Each array was identically treated with detection reagent and film.
Treatment with Ad-PDGF-B resulted in the phosphorylation of Akt in human gingival fibro-
blast cells at the late stage, which is similar to the immediate response to recombinant human
platelet-derived growth factor-BB protein. 1, Akt1; 2, Akt2; 3, Akt3; 4, pan-Akt; Ctrl, control.
Fig. 5. Sustained phosphorylation of Akt in adenoviral gene delivery. Western blotting was
used to examine the time curve of Akt phosphorylation after gene delivery. Human gingival
fibroblasts from three patients were tested and representative data are shown here. Human
gingival fibroblast cells were exposed to Ad-PDGF-1308 (multiplicity of infection = 200),
Ad-PDGF-B (multiplicity of infection = 200) or 20 ng/mL of recombinant human platelet-
derived growth factor-BB in serum-free medium for 2 h. Then, cell lysates at 1, 6, 12, 24, 48,
72 and 96 h were subjected to western blotting using antibodies to phosphor-Akt and
pan-Akt. The graphs show the relative ratio of phosphorylated Akt levels normalized to total
Akt (analyzed by densitometric scanning). Recombinant human platelet-derived growth
factor-BB induced transient Akt phosphorylation, which lasted about 24 h. However, with
Ad-PDGF-B transduction, the phosphorylation of Akt was first seen as early as 6 h post-
infection, and remained elevated for at least 96 h to a greater relative extent.
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growth factor-BB protein from the
Ad-PDGF-B-transduced human gingi-
val fibroblasts to be in the order of
40 ng of protein per 106 cells. This
was effective to maintain cell prolifer-
ation in serum-free medium (Fig. 2B).
Also it would provide an efficacious
dose of the growth factor in vivo for
periodontal wound healing applica-
tions and could abrogate the need for
continuous delivery compared with the
topical pulse administration of plate-
let-derived growth factor-BB protein
that typically results in the transient
(< 24 h) release of platelet-derived
growth factor-BB in vivo (16).
Platelet-derived growth factor is a
soluble protein that stimulates cell
proliferation and migration through
membrane receptors of the receptor
tyrosine kinase family. Platelet-derived
growth factor-A only binds to platelet-
derived growth factor-a receptor,
whereas platelet-derived growth factor-
B can bind to both a and b receptors.
Platelet-derived growth factor binding
to the receptors also activates a variety
of intracellular signaling molecules (3)
and the platelet-derived growth factor-
a and –b receptors activate many
overlapping signaling pathways. The
activated receptors phosphorylate a
large number of substrates (more than
20), including themselves, which initi-
ates a complex network of signaling
cascades. Activation of either the a or
the b receptor can stimulate cell
migration, although platelet-derived
growth factor-B is generally a stronger
inducer than platelet-derived growth
factor-A (30–32). In addition to their
traditional role as receptor tyrosine
kinases, platelet-derived growth factor-
a receptor and platelet-derived growth
factor-b receptor have been associated
with cell growth arrest (17). Lih et al.
showed that platelet-derived growth
factor-a receptor was highly expressed
during the cell growth arrest stage in-
duced by serum deprivation (33). Vaz-
iri et al. reported that serum
deprivation induced growth arrest
in G0 and is associated with increased
expression of platelet-derived growth
factor-b receptor (34). We previously
found that Ad-PDGF-A gene transfer
resulted in sustained activation and
subsequent downregulation of the
platelet-derived growth factor-a recep-
tor, a direct result of continued sig-
naling by ligand binding (22). Vaziri
et al. also found that the adenovirus
continuously produced platelet-derived
growth factor-AA dimers and that
prolonged platelet-derived growth fac-
tor expression activated and downreg-
ulated platelet-derived growth factor-a
receptor for an extended period of
time. Carmen et al. reported that
treatment with recombinant human
platelet-derived growth factor-BB
induced the downregulation of plate-
let-derived growth factor receptor in
mouse hepatic stellate cells (35). In the
present study we measured a similar
downregulation of both a and b
platelet-derived growth factor recep-
tors by Ad-PDGF-B gene transfer
within human gingival fibroblast cells.
The kinetics of platelet-derived growth
factor-a and platelet-derived growth
factor-b receptor protein expression in
human gingival fibroblast cells were
nearly identical: downregulated after
6 h post-transduction and maintained
at very low levels for at least 96 h
(Fig 3).
Protein phosphorylation is a funda-
mental mechanism for the regulation
of many aspects of cellular functions.
One of the important roles of protein
phosphorylation is in signal transduc-
tion pathways, which are regulated at
many levels, from the activation of cell-
surface receptors to the stimulation of
transcription factors. Detection of the
phosphorylation state of intracellular
proteins would provide valuable
information on the activation state of
human gingival fibroblasts following
the long-term delivery of platelet-
derived growth factor. In the present
study, by using a human phospho-
MAPK array, we simultaneously
assessed the phosphorylation of 23
different intracellular kinases, includ-
ing three major members of the MAPK
family (ERK1/2, JNK1-3 and p38),
Akt, GSK-3 and p70 S6 kinase. Our
results from the protein array (Fig. 4),
which were confirmed by western
blotting, showed that Akt activation
may play an important role by medi-
ating the effect of long-term platelet-
derived growth factor delivery in
human gingival fibroblasts. In our
experiment, adenovirus was delivered
to human gingival fibroblasts by tran-
sient transfection (only 2 h), which
explains in part why the phosphoryla-
tion levels of Akt at later time-points
were relatively low. Akt (also known as
protein kinase B), functions as a
downstream target of phosphatidyl-
inositol-3-kinase and plays a critical
role in controlling cell survival and
apoptosis (36,37). Akt is inactive in
serum-starved conditions, but is acti-
vated by various growth factors or
stimuli, including platelet-derived
growth factor (25). It is a general sur-
vival signal mediator, which inhibits
apoptosis by phosphorylating or inac-
tivating several downstream targets,
such as nuclear factor-jB, Bad, fork-
head transcription factors and caspase-
9 (38). Thus, the sustained activation
of Akt after adenoviral platelet-derived
growth factor-B delivery in human
gingival fibroblasts helps us to under-
stand, in more detail, a mechanism by
which PDGF gene therapy supports
tissue repair (24). This is also sup-
ported by the work of Mangi et al.,
which showed that mesenchymal stem
cells transduced with Akt1 can repair
infarcted myocardium, probably via
promoting cell survival after cell
transplantation (39). Recently, Akt
was also found to regulate the growth
arrest-related genes PDGFaR and
PDGFbR. Activation of Akt inhibits
the expression of PDGFaR and
PDGFbR via activating mTOR. This
suppression probably occurs as a result
of decreased transcription of PDGFR
and/or reduced mRNA half-life
(40,41). Therefore, the sustained
decrease of the platelet-derived growth
factor-a and -b receptors (Fig. 3) could
be partly caused by the prolonged
activation of Akt.
In conclusion, this study demon-
strated a high efficiency of PDGF-B
gene transfer into human gingival
fibroblasts using adenovirus, with
expression of the PDGF gene detected
up to 96 h post-infection. This has
promise for clinical applications as
direct application of recombinant
human platelet-derived growth factor-
BB for periodontal wound healing
applications has proven effective yet
typically displays a much shorter half-
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life. Our data also shows that specific
intracellular signaling pathways (i.e.,
those involving platelet-derived growth
factor receptors a and b, and Akt)
mediate unique responses to growth
factors via gene delivery within human
gingival fibroblasts. These data on
PDGF gene delivery contribute to
an improved understanding of these
pathways that are likely to play a role in
the control of clinical outcomes of
periodontal regenerative therapy.
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